OKYO Pharma (OKYO) Investor presentation summary

Corporate highlights and leadership

• Focus on rare ocular diseases with high unmet needs, targeting corneal and anterior segment conditions.

• Leadership team has extensive experience in ophthalmic drug development, commercialization, and regulatory strategy.

• Scientific advisory board includes leading ophthalmology experts from major academic institutions.

Lead asset and clinical development

• Urcosimod is a first-in-class, non-opioid, preservative-free eye drop targeting ChemR23 for neuropathic corneal pain (NCP).

• Demonstrated dual mechanism: modulates neuropathic pain and immune-mediated inflammation.

• Phase 2a trial showed 75% of patients achieved >80% pain reduction; mean VAS improvement of 5.5 points vs. 2.75 for placebo.

• Favorable safety profile with no serious adverse events in clinical studies.

• Phase 3 NEPTUNE trial design finalized, with topline data expected in Q4 2027.

Market opportunity and unmet need

• NCP is a severely debilitating, underdiagnosed condition with no FDA-approved therapies.

• Current treatments are limited and often involve off-label use of NSAIDs, steroids, or opioids, with significant side effects.

• Urcosimod is positioned as a specialty, premium-priced therapy for chronic pain and rare ocular disease markets.

• Claims-based epidemiology and payer research are underway to support regulatory and commercial strategy.